The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Trials · continued

Adjudicated events and why the definition matters — the long version posts 121–147

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

SC
sourced_claimsTL3Regular27 Apr 2025#121

Post #119 is right about the mechanism and I think understates the practical bit.

The question underneath Adjudicated events is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.

Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.

10 likes 15mo
RZ
ro.zielinskiTL227 Apr 2025#122

I would put moderate confidence on the mainstream reading of Adjudicated events and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.

23 likes 15mo
DV
dr.villanuevaTL3Physician28 Apr 2025#123
bac_water, post #47: What I would want before treating Adjudicated events as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing. Go to post

Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the practical magnitude. The event rate in each arm and the difference between them tells you how many people benefit.

That is what I would do. It may not be what is correct.

0 likes in reply to #47 15mo
SG
s.grimaldiTL228 Apr 2025#124

Worth separating two things that post #120 runs together.

Surrogate endpoints: an endpoint that is not the outcome that matters but is measured as a stand-in. HbA1c is a surrogate for long-term glucose control and the short-term complications it prevents. Weight loss is a surrogate for metabolic health and long-term outcomes. Surrogates are useful but not identical to the endpoint that matters.

Same conclusion as the reply above, reached differently, which is mildly reassuring.

3 likes 15mo
M
microgramsTL2Regular29 Apr 2025#125

Appreciated. The plain phrasing does more work here than a longer post would.

16 likes 15mo
AA
a.adeyemiTL229 Apr 2025#126

I had written a reply contradicting post #124 and deleted it. Here is what survived.

Marking my uncertainty on Adjudicated events explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.

31 likes 15mo
HO
h.oyelowoTL2Regular30 Apr 2025#127
r.petrov, post #35: Surrogate endpoints: an endpoint that is not the outcome that matters but is measured as a stand-in. HbA1c is a surrogate for long-term glucose control and the short-term complications it prevents. Weight loss is a surrogate for metabolic health and long-term outcomes. Surrogates are useful but not identical to the endpoint that matters. Go to post

Absolute and relative effects answer different questions. Write down the event rate in each arm and the difference between them; everything quotable is derived from those two numbers.

The honest answer is that it depends, and here is what it depends on.

1 like in reply to #35 15mo
MR
m.radichTL21 May 2025#128

If someone has run Adjudicated events properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.

6 likes 15mo
WT
week_threeTL1Member1 May 2025#129

For anyone finding this later: the short answer on Adjudicated events is that it depends on one thing, and the rest of the thread is people identifying which thing.

22 likes 15mo
GB
g.bakkenTL22 May 2025 · edited#130
i.guerrero, post #48: My experience of Adjudicated events contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that. Go to post

Where I part company with post #128, and it is a narrow parting.

The figure that circulates in coverage is almost always whichever estimand gives the larger effect. That is not fraud; it is selection, and it is why the paper matters more than the summary.

Reporting the observation and leaving the explanation open deliberately.

0 likes in reply to #48 15mo
AK
a.kwiatkowskiTL2Member2 May 2025#131

Coming back to post #127, because the follow-up matters more than the original answer.

Adjudicated events came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.

2 likes 15mo
NK
n.kaufmannTL23 May 2025#132
isotonic_sheet, post #119: The bit of Adjudicated events that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge. Go to post

A note on how Adjudicated events gets discussed rather than on Adjudicated events itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.

0 likes in reply to #119 15mo
N
NardoneTL2Member3 May 2025 · edited#133

Multiplicity and multiple comparisons: if a trial tests many hypotheses, the chance of a false positive on at least one by random chance increases. This is why pre-specification of the primary endpoint matters and why secondary endpoints are weaker evidence.

A guess, clearly labelled as one.

19 likes 15mo
TV
t.vargaTL24 May 2025#134

Picking up post #131: that is the part I would want checked first.

Worth stating the null on Adjudicated events before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.

8 likes 15mo
MM
methods_marginTL3Regular4 May 2025#135

I had written a reply contradicting post #131 and deleted it. Here is what survived.

Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the practical magnitude. The event rate in each arm and the difference between them tells you how many people benefit.

0 likes 15mo
EB
e.bakkenTL25 May 2025#136

Confirming post #135 from a second method, which matters more than confirming it from a second person.

Subgroup analyses are hypothesis-generating unless pre-specified and adequately powered, and almost none are the second. The interaction test matters more than the subgroup point estimate.

0 likes 15mo
I
IRenaudinTL2Member5 May 2025#137
a.cabrera, post #78: Dropout is information: high dropout rates can indicate tolerability problems or lower efficacy than the summary suggests. Where the analysis handled dropouts matters. An intention-to-treat analysis with many dropouts can give a smaller apparent effect than per-protocol analysis. One more caveat and then I will stop qualifying: the… Go to post

My position on Adjudicated events is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.

13 likes in reply to #78 15mo
SC
s.chowdhuryTL3Regular6 May 2025#138

The arithmetic on Adjudicated events is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.

4 likes 15mo
OA
o.abrahamsenTL3Regular6 May 2025#139

Dropout is information: high dropout rates can indicate tolerability problems or lower efficacy than the summary suggests. Where the analysis handled dropouts matters. An intention-to-treat analysis with many dropouts can give a smaller apparent effect than per-protocol analysis.

If anyone can point at the primary source I would be grateful.

0 likes 15mo
MN
m.nwosuTL27 May 2025#140

Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method (was it truly random or could someone predict the next assignment), concealment (could randomisation be subverted), blinding (who was blinded and why or why not), completeness of outcome reporting.

I would rather post the uncertainty than round it away.

27 likes 15mo
SC
s.coelhoTL27 May 2025#141

Before the thread moves on from Adjudicated events — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.

0 likes 15mo
JM
j.mwangiTL4 Moderator8 May 2025 · edited#142

A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened had everyone continued. Both are legitimate and they give different numbers.

4 likes 15mo
EK
e.kuuselaTL28 May 2025#143
k.redgrave, post #79: That is clearer than the version I had in my head. Thank you. Go to post

Adding the boring version of Adjudicated events, because the interesting version keeps getting posted and the boring one is usually right.

Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.

13 likes in reply to #79 15mo
C
chromatogramTL4Analytical chemist9 May 2025#144
l.sarkissian, post #111: Multiplicity and multiple comparisons: if a trial tests many hypotheses, the chance of a false positive on at least one by random chance increases. This is why pre-specification of the primary endpoint matters and why secondary endpoints are weaker evidence. The step people skip is the one I have spelled out. Go to post

Worth separating two things that post #142 runs together.

The confident answers on Adjudicated events and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.

27 likes in reply to #111 15mo
BV
b.vanheckeTL29 May 2025#145

Absolute and relative effects answer different questions. Write down the event rate in each arm and the difference between them; everything quotable is derived from those two numbers.

Correct me on the arithmetic if it is wrong; I would rather know.

0 likes 15mo
PE
ppm_errorTL3Analytical chemist10 May 2025#146

Surrogate endpoints: an endpoint that is not the outcome that matters but is measured as a stand-in. HbA1c is a surrogate for long-term glucose control and the short-term complications it prevents. Weight loss is a surrogate for metabolic health and long-term outcomes. Surrogates are useful but not identical to the endpoint that matters.

If the premise is wrong, everything after it is decoration.

2 likes 15mo
RP
r.petrovTL210 May 2025#147

Picking up post #144: that is the part I would want checked first.

Worth separating Adjudicated events as a question about the compound from Adjudicated events as a question about the documentation. They get answered by different people and only one of them is answerable here.

8 likes 15mo
Promoted into the documentation commons. The content of this topic is maintained at STEP 1 — trial digest, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Suggested topics

TopicParticipantsRepliesViewsActivity
Non-inferiority margins: how they are chosen and how they are abused
Posting this under the heading it deserves: Non-inferiority margins: how they are chosen and how they are abused Everything below is what sits behind that. A question about non-inferiority margins that I…
NTKCTDOPA+42 46 10k 5mo
Subgroup analyses: pre-specified versus discovered — a second dataset
On the subject in the title: Subgroup analyses: pre-specified versus discovered — a second dataset Working notes rather than a conclusion. Posting a small dataset on Subgroup analyses. It is mine, it is…
IDAMCILDC+71 79 906 3mo
[2026 update] Composite endpoints and the component doing the work
On the subject in the title: Composite endpoints and the component doing the work Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-4 ( Lancet , 2021) and…
CRSFDVFJP+76 87 994 3mo
Non-inferiority margins: how they are chosen and how they are abused — a second dataset
Non-inferiority margins: how they are chosen and how they are abused — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Non-inferiority…
FTJIRHAAP+32 37 574 5mo
Comparators chosen for regulatory reasons rather than clinical ones — one year on
Comparators chosen for regulatory reasons rather than clinical ones — one year on — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Comparators chosen for…
SGLIAKADYR+82 87 1.1k 12mo

Related topics — sharing the tags intention to treat, estimand, randomised trial

TopicParticipantsRepliesViewsActivity
Non-inferiority margins: how they are chosen and how they are abused — a second dataset
Non-inferiority margins: how they are chosen and how they are abused — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Non-inferiority…
FTJIRHAAP+32 37 574 5mo
Second pass at: Retatrutide dose escalation in the published trials
Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…
BRNKISTM+115 125 30k 2y
Primary endpoint hierarchies and why order matters
Primary endpoint hierarchies and why order matters Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about primary endpoint hierarchies in a thread last spring and…
LCDSFWCLNK 4 308 3mo
Semaglutide and alcohol: what is actually documented
Posting this under the heading it deserves: Semaglutide and alcohol: what is actually documented Everything below is what sits behind that. I would like to know what people here actually do about semaglutide…
SFNNRGCSAZ+14 18 10k 2d
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about SELECT in a thread…
CNACSE 2 1.9k 5mo